SBBP Strongbridge Biopharma plc gains 22% Jul 13, 2017

Strongbridge Biopharma plc, a biopharmaceutical company, through its subsidiary, Cortendo AB (publ), develops, acquires, and commercializes product candidates that target rare diseases. The company's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is in the Phase 3 trial for the treatment of endogenous Cushing's syndrome. It also has two product candidates, COR-004 and COR-005 in Phase 2 clinical development to treat acromegaly. In addition, it is developing BP-2001, a pre-clinical product candidate for the treatment of diabetes. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania. http://www.priceseries.com/trade/SBBP-Strongbridge-Biopharma-plc-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2017062220170713.html